We are doing a randomized multi-center international clinical trial with a target population of hepatitis B virus-associated hepatocellular carcinoma. In order to develop PHY906 as a drug, we formed a company called Yiviva, in which Yale is a co-founder… Read…
While a longer recovery course might be expected for someone such as Herbert who faced a more severe illness, there’s also concern for more permanent lung damage, according to Dr. Ronald DePinho, professor and past president of MD Anderson Cancer…
Oncoheroes Biosciences, currently working on the clinical development of volasertib, a potential new drug for rhabdomyosarcoma patients, is honored to announce the receipt of funding from Super Sam Foundation, a pediatric cancer non-profit. Read more: https://oncoheroes.com/insights-news-1/2020/5/29/oncoheroes-biosciences-and-super-sam-foundation-walking-together-for-the-pediatric-cancer-heroes
Oncoheroes Biosciences, a biotech focused exclusively on advancing new therapies for children with cancer, receives another endorsement from a childhood cancer non-profit. The support received by The Gregory Foundation for Cancer Research will help accelerate the clinical drug development of…
Three Decades of NFCR Basic and Translational Research Funding to Primary Investigator Dr. Yung-Chi Cheng and Project Advances New Systems Biology Paradigm for Cancer Treatment World-First Phase II Multi-Regional Clinical Trial for a Botanical Cancer Drug Candidate ROCKVILLE, MD –…
Mr. Peikwen Cheng is Co-founder and CEO of Yiviva, a biotechnology start-up that develops first-in-class therapeutics. The company developed YIV906, an herbal mixture based on an 1,800-year-old Chinese formula. A number of clinical studies show YIV906 reduces the harmful adverse…
By Sujuan Ba, Ph.D. In 1975 the United Nations General Assembly designated March 8 as International Women's Day. While the original focus was about celebrating the economic, political, and social achievements of women, to many this has become simply an…
ROCKVILLE, MD & BOSTON, MA – An AIM-HI Accelerator Fund portfolio company exclusively focused on the development of pediatric cancer therapeutics has garnered recognition and additional funding. Oncoheroes Biosciences Inc. won the Squinto-LePera Award at the Lyfebulb-Helsinn Cancer Innovation Summit…
More than 20 years ago, Yale pharmacology professor Yung-Chi Cheng, a leader in drug development for hepatitis B, cancer, and HIV, had a radical idea: What if he could unlock the therapeutic potential of ancient Chinese medicines for treating cancer?…
A drug and drug delivery candidate technology, research into which has been funded by the National Foundation for Cancer Research (NFCR), has recently been approved by the U.S. Food and Drug Administration (FDA) for the initiation of human clinical trials.…
